4CMenB journey to the 10-year anniversary and beyond
| Title: | 4CMenB journey to the 10-year anniversary and beyond |
|---|---|
| Authors: | Véronique Abitbol, Federico Martinón-Torres, Muhamed-Kheir Taha, Terry Nolan, Alessandro Muzzi, Stefania Bambini, Ray Borrow, Daniela Toneatto, Laura Serino, Rino Rappuoli, Mariagrazia Pizza |
| Source: | Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024) |
| Publisher Information: | Taylor & Francis Group, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Immunologic diseases. Allergy LCC:Therapeutics. Pharmacology |
| Subject Terms: | 4CMenB, Bexsero, cross-protection, effectiveness, impact, Neisseria meningitidis, Immunologic diseases. Allergy, RC581-607, Therapeutics. Pharmacology, RM1-950 |
| More Details: | The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 countries worldwide. Real-world evidence (RWE) from the last decade confirms its effectiveness and impact, with infant immunization programs showing vaccine effectiveness of 71–95% against invasive MenB disease and cross-protection against non-B serogroups, including a 69% decrease in serogroup W cases in 4CMenB-eligible cohorts in England. RWE from different countries also demonstrates the potential for additional moderate protection against gonorrhea in adolescents. The real-world safety profile of 4CMenB is consistent with prelicensure reports. Use of the endogenous complement human serum bactericidal antibody (enc-hSBA) assay against 110 MenB strains may enable assessment of the immunological effectiveness of multicomponent MenB vaccines in clinical trial settings. Equitable access to 4CMenB vaccination is required to better protect all age groups, including older adults, and vulnerable groups through comprehensive immunization policies. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 21645515 2164-554X 2164-5515 |
| Relation: | https://doaj.org/toc/2164-5515; https://doaj.org/toc/2164-554X |
| DOI: | 10.1080/21645515.2024.2357924 |
| Access URL: | https://doaj.org/article/380746a45f9448248f21e680320ecf7a |
| Accession Number: | edsdoj.380746a45f9448248f21e680320ecf7a |
| Database: | Directory of Open Access Journals |
| ISSN: | 21645515 2164554X |
|---|---|
| DOI: | 10.1080/21645515.2024.2357924 |
| Published in: | Human Vaccines & Immunotherapeutics |
| Language: | English |